Hvor langt skal aksjen gå fra NOK 0,88 og oppover?
Mange sier at aksjen skal gå veldig høyt. Hvis det blir suksess hvor høyt er det realistisk at aksjen kan gå eller bli solgt for til en av de store i bransjen?
Snakker man om 30 kroner eller over 100 kroner eller har noen andre bedre forslag.
Snakker man om 30 kroner eller over 100 kroner eller har noen andre bedre forslag.
-
«
- 1
- 2 »
Gullhaugen
12.12.2024 kl 13:01
604
Så CIRCIO er den perfekte plattform kandidaten.for Astra
Circio med nye data på genterapi-plattform
Selskapet har lagt frem nye og statistisk signifikante data på sin plattform for sirkulær RNA på genterapikonferansen ESGCT i Roma.
Bare vent til noen større hvaler får denne på radaren. Da skal du få se hva som skjer.Atlas har ikke allverden med aksjer å pøse ut.
Circio med nye data på genterapi-plattform
Selskapet har lagt frem nye og statistisk signifikante data på sin plattform for sirkulær RNA på genterapikonferansen ESGCT i Roma.
Bare vent til noen større hvaler får denne på radaren. Da skal du få se hva som skjer.Atlas har ikke allverden med aksjer å pøse ut.
Redigert 12.12.2024 kl 13:11
Du må logge inn for å svare
JosefK
12.12.2024 kl 13:34
561
Du svarer fremdeles ikke på spørsmålet. PCI var innom Astra uten at det hjalp noe.
Bullinvestor
13.12.2024 kl 13:15
406
Gullhaugen skrev Kjøp med begge hendene nå og Hold
Kjøper du enda her? Oncoinvent som er børsnotert i dag opp rundt 87% ja det hjelper vel ikke så mye når kursen for mange år siden var mellom 30-60 kr.. viktig å huske de fleste slike selskap er jo egentlig ikke no mer enn et Flax lodd..
paali89
I går kl 12:20
250
Due to substantial interest from existing shareholders and new investors for the
ongoing Warrants exercise, the board of directors of the Company has resolved to
open for subscription of additional new shares at an issue price of NOK 0.60
(i.e. equal to the Warrant Exercise Price).
A total of 13,864,852 warrants (Nw.: frittstående tegningsretter) (the
"Warrants") were issued in connection with the Rights Issue. Each Warrant gives
the holder (the "Holder") a right to subscribe for one new share in the Company
at an exercise price per share of NOK 0.60 (the "Warrant Exercise Price"). The
Warrants must be exercised no later than 16:30 (CET) on 18 December 2024 (the
"Warrant Expiry Time").
The Company has been informed that certain holders will not exercise their
Warrants, including Atlas Special Opportunities LLC ("Atlas") which holds 6
million Warrants. These Warrants have been made available to the Company for
distribution for free to investors who contact the Company indicating their
interests in acquiring Warrants and who will exercise them prior to the Warrant
Expiry Time (the "Potential Investors"). Any funds raised from the exercise of
Warrants will reduce and delay the requirement to draw future tranches from
Atlas under the convertible bond financing facility.
In the event Potential Investors are interested in exercising more Warrants than
those available for distribution by the Company, the board of directors is
contemplating carrying out a private placement by the issuance of up to
4,903,934 additional new shares at an issue price of NOK 0.60 per share to
satisfy such additional demand by use of the authorization to increase the share
capital granted by the general meeting on 19 June 2024.
Potential Investors interested in exercising Warrants and subscribing for new
shares are requested to complete an application form (the "Application Form")
attached to this notice. The Application Form must be completed and received by
the Company by e-mail at contact@circio.com before 16.00 hours (CET) on 17
December 2024.
The minimum exercise and subscription amount per Potential Investor is NOK
50,000, which corresponds to 83,333 shares. The allocation of Warrants and
private placement shares among Potential Investors will be at the sole
discretion of the Company.
The Company will on 18 December 2024 contact the Potential Investors who are
being allocated Warrants and private placement shares to inform them of the
number of Warrants and shares allocated to them and provide information on the
allocation and total payment information.
ongoing Warrants exercise, the board of directors of the Company has resolved to
open for subscription of additional new shares at an issue price of NOK 0.60
(i.e. equal to the Warrant Exercise Price).
A total of 13,864,852 warrants (Nw.: frittstående tegningsretter) (the
"Warrants") were issued in connection with the Rights Issue. Each Warrant gives
the holder (the "Holder") a right to subscribe for one new share in the Company
at an exercise price per share of NOK 0.60 (the "Warrant Exercise Price"). The
Warrants must be exercised no later than 16:30 (CET) on 18 December 2024 (the
"Warrant Expiry Time").
The Company has been informed that certain holders will not exercise their
Warrants, including Atlas Special Opportunities LLC ("Atlas") which holds 6
million Warrants. These Warrants have been made available to the Company for
distribution for free to investors who contact the Company indicating their
interests in acquiring Warrants and who will exercise them prior to the Warrant
Expiry Time (the "Potential Investors"). Any funds raised from the exercise of
Warrants will reduce and delay the requirement to draw future tranches from
Atlas under the convertible bond financing facility.
In the event Potential Investors are interested in exercising more Warrants than
those available for distribution by the Company, the board of directors is
contemplating carrying out a private placement by the issuance of up to
4,903,934 additional new shares at an issue price of NOK 0.60 per share to
satisfy such additional demand by use of the authorization to increase the share
capital granted by the general meeting on 19 June 2024.
Potential Investors interested in exercising Warrants and subscribing for new
shares are requested to complete an application form (the "Application Form")
attached to this notice. The Application Form must be completed and received by
the Company by e-mail at contact@circio.com before 16.00 hours (CET) on 17
December 2024.
The minimum exercise and subscription amount per Potential Investor is NOK
50,000, which corresponds to 83,333 shares. The allocation of Warrants and
private placement shares among Potential Investors will be at the sole
discretion of the Company.
The Company will on 18 December 2024 contact the Potential Investors who are
being allocated Warrants and private placement shares to inform them of the
number of Warrants and shares allocated to them and provide information on the
allocation and total payment information.
elnomi
I går kl 13:25
191
Er det noe «fundamentalt galt»?
I CRNA er det enten løpende konverteringer («dødsspirallån») fra Atlas ellers så er det konvertering av warrants til aksjer.
Vanligvis så gjennomfører selskaper en emisjon og med det sikrer langsiktig kapital, så ikke i CRNA.
Noen som kan forklare dette?
I CRNA er det enten løpende konverteringer («dødsspirallån») fra Atlas ellers så er det konvertering av warrants til aksjer.
Vanligvis så gjennomfører selskaper en emisjon og med det sikrer langsiktig kapital, så ikke i CRNA.
Noen som kan forklare dette?
-
«
- 1
- 2 »